Avac Event

Long-Acting Injectable Cabotegravir for PrEP: Understanding Results of HPTN 083 & 084 and key areas for advocacy

[UPDATE]: In December of 2021, the FDA approved CAB-LA as PrEP, making it the first injectable PrEP to be added to the toolbox of proven prevention methods. The other methods are male and female condoms, daily oral PrEP, voluntary medical male circumcision and the Dapivirine Vaginal Ring.

On May 3, AVAC held a webinar where you can listen to the researchers who led the studies about long-acting injectable PrEP strategy and advocates who are leading essential advocacy efforts around the introduction of CAB-LA.

On the call, lead trial investigators Sinead Delany-Moretlwe from HPTN 084 and Raphy Landovitz from HPTN 083 provided updates, and we were joined by AVAC’s Emily Bass, Chiluyfa Kasanda from TALC in Zambia, Richard Lusimbo from Pan Africa ILGA, and Sibongile Maseko who is an independent consultant and women’s health advocate based in Eswatini.

Recording and Slides: YouTube / Civil Society Advocates’ Slides / Sinead Delaney-Moretlwe’s Slides / Raphy Landovitz’s Slides